ClinicalTrials.gg
RecruitingNCT06578650Updated Jun 18, 2026

A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

An observational study in Surgical Wound, sponsored by Acera Surgical, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Acera Surgical, Inc. (part of Solventum) · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 129 studies in Surgical Wound with a site in United States — 17 open to participants now, 21 under way, none of them phase 3. Surgical Wound · United States.

Planned enrollment
11th of 18
34 · median 46
Started
2024
with 5 others
Observational
18 of 129
4 open now
Primary completion
2027-08
later than 13 of 20 live
Registered
119th of 129
by date

Among the 129 studies in Surgical Wound with a site in United States, this one is the 11th largest by planned enrollment of the 18 observational ones that give a count, is one of 6 that started in 2024, is one of 18 observational ones, reaches primary completion later than 13 of the 20 other live ones, and was the 119th registered.

Surgical Wound

315 studies on the registry are indexed under Surgical Wound; 57 are open to participants now.

Browse Surgical Wound studies →

Open to participants now

17 of the 129 studies in Surgical Wound with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Surgical Wound studies recruiting now, 19 (58%) set no upper age limit and 10 (30%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Surgical Wound with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational prospective study is to evaluate wound healing outcomes in resection wounds resulting from surgical removal of cutaneous malignancies treated with a synthetic electrospun fiber matrix. This study intends to quantify the time from initial resection and product application to time of complete granulation of the wound bed in weeks.

03

Conditions studied

  • Surgical Wound

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be enrolled in a University Hospital Setting

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is at least 18 years old
  2. Patient plans to undergo surgical resection of a cutaneous neoplasm
  3. Patient is willing and capable of complying with all protocol requirements
  4. Patient or legally authorized representative (LAR) is willing to provide written prior to participation in study
  5. Post-resection surgical wound with a surface area of ≥4 cm2 and ≤ 36cm2

Exclusion criteria

Exclusion Criteria:

  1. Inability to give or to complete the procedures required for study completion
  2. Patient has been previously enrolled into this study, or is currently participating in another drug or device study that has not reached its primary endpoint
  3. Patient is pregnant, breast feeding or planning to become pregnant
  4. Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)
  5. Patients receiving any immunotherapy, radiation, or chemotherapy within the past four weeks prior to resection surgery.
  6. Patient has a less than six months as assessed by the investigator
  7. Patient has an additional non-study related wound within 3 cm of the study wound
  8. Study wound is located on the hands or feet
  9. Patient has been diagnosed with osteomalacia
  10. Resection defect from a squamous cell carcinoma arising from a chronic wound
  11. Patient has an uncontrolled thyroid disorder
  12. A1c > 12% within 3 months prior to enrollment in patients with a known history of diabetes
  13. Patient has a > 34.9
  14. Patient has used any tobacco product within the past 30 days prior to surgery
  15. Patients with chronic kidney disease on peritoneal or hemodialysis, or with an estimated less than 15mL/min
  16. Patients with severe liver disease with active cirrhosis defined as a gross ascites upon clinical exam or a Model for End-stage Liver Disease (MELD)-Na score greater than 15
  17. Patient not in reasonable metabolic control in the judgement of the investigator
  18. Patient has a known history of poor compliance with medical treatment
  19. Patient has a history of radiotherapy to wound bed of interest
  20. Patient has been diagnosed with at least one of the following connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis
  21. Active infection, undrained abscess, or critical colonization of the wound with bacteria in the judgement of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34 participants (estimated)
Patient registry
No

Interventions

  • DeviceSynthetic Electrospun Fiber Matrix

    Patients who are eligible for enrollment will be treated with Synthetic Electrospun Fiber Matrix immediately after surgical resection to the resulting wound

06

What researchers measure

Primary outcomes

  1. Time to wound bed granulation

    Time from initial resection and product placement to the time of at least 75% wound bed granulation using a modified Bates-Jenson Scale. The Bates-Jenson Scale for Granulation Tissue ranges from: 1=Skin intact or partial thickness wound, to: 5=No granulation tissue present. Wounds are considered "granulated" upon receiving a rating of 2 (Bright, beefy red;75% to 100% of wound filled \&/or tissue overgrowth) or less upon investigator assessment. Lower scores are indicative of better outcomes.

    Time frame: Weekly assessments until granulation achieved or up to 6 weeks following resection surgery

Secondary outcomes

  1. Time to complete wound healing

    Total healing time will be documented (in days) at the final follow-up appointment by calculating the difference using the resection visit and "healed" visit dates.

    Time frame: Until healed or until 16 weeks post resection

  2. Patient pain

    Pain reported by patient on a Visual Analogue Scale (VAS), with 0 indicating no pain and 10 indicating worst pain possible. Lower scores are indicative of a better outcome

    Time frame: Weekly for up to six weeks post resection

  3. Time to skin grafting

    Time from resection and product place until skin grafting (if patient elects to do so)

    Time frame: Weekly for up to 6 weeks post-resection

  4. Skin graft "take" rate

    Percent of skin graft incorporation as assessed by the investigator, in patients who elect to undergo skin grafting

    Time frame: 1 week after skin graft application

  5. Tissue flap take rate

    Percent of successful tissue graft incorporation as assessed by the investigator, in patients who elect to undergo tissue flap procedures

    Time frame: 1 week after tissue flap procedure

Other outcomes

  1. Scar quality

    Scar quality using a Vancouver Scar Scale (VSS). The scale ranges from 0 (normal skin) to 13 (worst scar outcome). Lower scores are indicative of a better scar outcome

    Time frame: At the time of complete wound closure and at the 6 month post-resection follow up

  2. Infection rate and severity

    Incidence and severity of wound bed infection (if one occurs) per CTCAE V5.0 definitions ranging from 1 (localized, local intervention indicated) to 5 (death). Lower scores are indicative of milder infections

    Time frame: to be assessed at each visit for up to 6 months post resection

  3. Skin Graft Failure

    Incidence of inadequate skin graft adherence to the underlying wound bed as assessed by the investigator in patients who have received a skin graft

    Time frame: To be assessed at each post skin graft visit for up to 6 months post-resection

  4. Tissue flap failure

    Incidence of complete flap necrosis or need for total flap removal in patients who receive a tissue flap

    Time frame: Each post-flap follow up visit for up to 6 months post-resection

  5. Incidence of local skin cancer recurrence

    local recurrence of skin cancer

    Time frame: at the 6 month post-resection follow up

07

Study locations

1 of 1 sites recruiting
  • University Nevada - Las Vegas
    Las Vegas, Nevada 89102, United States
    Recruiting
    • Michelle Tomasino, CHPSE · Contactmichelle.tomasino@unlv.edu · 702-895-4923
    • Brian Ward, MD, PhD, FACS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2027, 34 months after the start.

Of 31 observational studies under Surgical Wound, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 143. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 29, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Oct 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06578650
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Oct 31, 2024
Primary completion
Aug 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Matthew MacEwan, PhD
Contact
macewan@acera-surgical.com
440-477-1890

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion